[go: up one dir, main page]

Nieves-Colón et al., 2022 - Google Patents

Clotting factor genes are associated with preeclampsia in high-altitude pregnant women in the Peruvian Andes

Nieves-Colón et al., 2022

View HTML @Full View
Document ID
3392494443823999293
Author
Nieves-Colón M
Rivera K
Sandoval K
Dávalos V
Lencinas L
Mendoza-Revilla J
Adhikari K
González-Buenfil R
Chen J
Zhang E
Sockell A
Ortiz-Tello P
Hurtado G
Salas R
Cebrecos R
Choque J
Choque F
Pilco G
Rawls E
Eng C
Huntsman S
Burchard E
Ruiz-Linares A
Gonzalez-Jose R
Bedoya G
Rothhammer F
Bortolini M
Poletti G
Gallo C
Bustamante C
Baker J
Gignoux C
Wojcik G
Moreno-Estrada A
Publication year
Publication venue
The American Journal of Human Genetics

External Links

Snippet

Preeclampsia is a multi-organ complication of pregnancy characterized by sudden hypertension and proteinuria that is among the leading causes of preterm delivery and maternal morbidity and mortality worldwide. The heterogeneity of preeclampsia poses a …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Hellwege et al. Mapping eGFR loci to the renal transcriptome and phenome in the VA Million Veteran Program
Nieves-Colón et al. Clotting factor genes are associated with preeclampsia in high-altitude pregnant women in the Peruvian Andes
US20240038396A1 (en) Methods and systems for determining risk of a pregnancy complication occurring
Bianchi From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges
Ponte et al. Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease
Haritunians et al. Genetic predictors of medically refractory ulcerative colitis
Cummings et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype
Paquette et al. A comprehensive assessment of associations between prenatal phthalate exposure and the placental transcriptomic landscape
KR20210100650A (en) Ancestor-specific genetic risk score
Saffari et al. Effect of maternal preconceptional and pregnancy micronutrient interventions on children's DNA methylation: findings from the EMPHASIS study
Granell et al. A meta-analysis of genome-wide association studies of childhood wheezing phenotypes identifies ANXA1 as a susceptibility locus for persistent wheezing
Barroso The importance of increasing population diversity in genetic studies of type 2 diabetes and related glycaemic traits
Nunziato et al. Multi-gene panel testing increases germline predisposing mutations’ detection in a cohort of breast/ovarian cancer patients from Southern Italy
Ballesteros et al. DNA methylation in gestational diabetes and its predictive value for postpartum glucose disturbances
Kwak et al. Sequencing cell-free fetal DNA in pregnant women with GCK-MODY
Pasanen et al. Identifying atopic dermatitis risk loci in 1,094,060 individuals with subanalysis of disease severity and onset
Leseva et al. Differential gene expression and limited epigenetic dysregulation at the materno-fetal interface in preeclampsia
Smits et al. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre‐eclampsia in nulliparous women: results from the SCOPE study
Li et al. Identification of genes involved in energy metabolism in preeclampsia and discovery of early biomarkers
Carrizosa-Molina et al. Methylation analysis by targeted bisulfite sequencing in large for gestational age (LGA) newborns: the LARGAN cohort
Pérez-Gimeno et al. Development of a genetic risk score to predict the risk of hypertension in European adolescents from the HELENA study
Manuck et al. Pharmacogenomics of 17‐alpha hydroxyprogesterone caproate for recurrent preterm birth: a case–control study
Kim et al. Genetic differences according to onset age and lung function in asthma: a cluster analysis
Liang et al. Genetic susceptibility, mendelian randomization, and nomogram model construction of gestational diabetes mellitus
Badillo Rivera et al. Clotting factor genes are associated with preeclampsia in high altitude pregnant women in the Peruvian Andes